Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A person must give their signed consent, or have a legal representative do so on their behalf.
• Patients must be female, aged 18 to 75 years old.
• Patients must have a good general physical functioning level, measured on a standard scale (ECOG score of 0 or 1 — confirm with trial site if unsure what this means).
• Patients must be expected to live for at least 6 months.
• The cancer must be a specific type of cervical cancer: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
• Patients must be able to provide a stored tumour tissue sample from within the past 2 years, or be willing to have a new biopsy taken.
• There must be at least one measurable area of cancer that can be tracked using standard imaging guidelines (RECIST 1.1).
• Patients must have received only one prior standard treatment for their cancer, with specific conditions depending on whether that treatment included immunotherapy (confirm exact requirements with trial site).
• Blood pressure, whether or not the patient takes blood pressure medication, must be below 140/90 mmHg at rest.
• Blood test results must meet minimum levels for white blood cells, neutrophils, platelets, and haemoglobin, without recent transfusions or growth factor medicines in the past 7 days.
• Liver function blood test results must fall within acceptable ranges for liver enzymes, bilirubin, and albumin.
• Blood clotting test results must fall within acceptable ranges (and the patient must not be on blood-thinning or clotting medicines at the time of testing).
• Kidney function test results must fall within acceptable ranges for urea, creatinine, and urine protein levels.
• Patients of childbearing potential must have a negative pregnancy blood test within 7 days before starting treatment, must not be breastfeeding, and must agree to use effective contraception throughout the study and for 180 days after the last dose.
• Patients must be willing and able to follow the study requirements reliably.

Who may not be able to join:

• People with certain serious or unstable health conditions, including recent serious infections, heart attack, heart failure, stroke, uncontrolled diabetes, or significantly reduced lung function.
• People with a history of autoimmune diseases, such as lupus, rheumatoid arthritis, or similar conditions.
• People with HIV, AIDS, or active hepatitis B or C infection.
• People who have received a live attenuated vaccine (a certain type of vaccine) within 28 days before starting the study, or who expect to receive one during the study.
• People whose cancer is close to or growing into major blood vessels in a way that the treating doctor judges to carry a high risk of serious bleeding.
• People who have previously been treated with the specific study drugs anlotinib or cadonilimab.
• People with evidence of active tuberculosis infection within the past year.
• People who have been diagnosed with another cancer within the past 5 years (certain treated skin cancers and cervical pre-cancers may be exceptions — confirm with trial site).
• People who have had major surgery within 28 days before joining the trial (minor procedures such as diagnostic biopsies are generally allowed).
• People who have had a blood clot event such as stroke, deep vein thrombosis, or pulmonary embolism within the past 6 months.
• People who have previously had, or are planned to have, a bone marrow or organ transplant.
• People with a history of significant bowel obstruction, bowel surgery, bowel diversion, or a fistula connecting the bowel to the skin.
• People who have coughed up blood recently, or who have had significant bleeding from any source within the past 3 months, or who have a known tendency to bleed or clot abnormally.
• People with visible blood in their urine or other signs of active bleeding from the urinary system.
• People currently receiving or requiring ongoing treatment with blood-thinning medicines (such as warfarin or heparin) or high-dose antiplatelet medicines (such as high-dose aspirin or clopidogrel).
• People with a known allergy to anlotinib, cadonilimab, or any of their ingredients.
• People who have taken part in another clinical drug trial within the past 4 weeks, or within 5 half-lives of the last study drug they received (whichever is longer).
• People with a history of substance abuse, alcohol dependence, or drug addiction.
• People with severe cognitive impairment or an unstable mental health condition.
• People who, in the treating doctor's judgement, have other serious medical, personal, or social circumstances that could affect their safety or the reliability of the trial data.

Important: Always verify eligibility with the trial site directly before applying.